Immunotherapy for prevention of postoperative recurrence in pancreatic cancer using cell therapy and vaccine therapy

点击翻译按钮获取中文摘要

(1)Thirty patients with pancreatic cancer were treated by immunotherapy using MUC1-CTL after curative resection. Only 3 patient (10%) had liver recurrence. However, 19 patients (63%) had local recurrence. One year, 2 year, and 3 year survival rate were 83.3%, 32.4%, and 19.9%, respectively. This immunotherapy may prevent liver metastasis after surgery, but can not control local recurrence.(2)To evaluate safety and immunological responses, we conducted a phase I study of personalized peptide vaccination for pancreatic cancer patients (n=11). Namely, pre-vaccination peripheral blood mononuclear cells were screened for their reactivity in vitro to each of 14 or 16 peptides in HLA-A24(+) or -A2(+) patients, and only the reactive peptides (maximum:4) were vaccinated in vivo. This regimen was generally well tolerated, although inflammatory reactions at the injection site were observed in 7 patients. Delayed-type hypersensitivity to peptides used for vaccination was observed in 7 patients. Increased cellular and humoral immune responses to at least one of peptides used for vaccination were observed in the post-vaccination PBMCs and sera from 4 of 8 patients and 4 of 10 patients tested, respectively. The 6- and 12-month survival rates for patients who received >3 vaccinations (n=10) were 80% and 20%, respectively. Due to tolerability and capability of inducing specific immunity, further development of personalized peptide-based immunotherapy for pancreatic cancer patients is warranted.(3)We performed MUC1-CTL+personalized peptide-based immunotherapy in 3 patients undergone curative resection for pancreatic cancer. All patients still alive without recurrence.(4)Fifteen patients with unresectable or recurrence pancreatic cancer were treated with MUC1-CTL+MUC1 peptide stimulated dendritic cells (DC) therapy. One patients had CR and 4 patients had SD. No severe side effects was observed.